Aldeyra has resubmitted its new drug application for reproxalap, an investigational dry eye treatment, which contained new ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...

Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease: Basel Tuesday, June 17, 2025, 09:00 Hrs [IST] Roche announced its decision to proceed ...

Adults with unresectable stage III or IV melanoma maintained similar progression-free disease control with 1- or 2-year ...

Vaccines have had a major impact on the control of infectious disease, most recently by helping to combat the COVID-19 pandemic. Prophylactic cancer vaccines have prevented several malignancies by ...

Investing.com -- Dyne Therapeutics, Inc. (Nasdaq:DYN) stock fell 23% after the company announced an updated plan for obtaining U.S. Accelerated Approval for DYNE-101 in myotonic dystrophy type 1 (DM1) ...

Ventyx Biosciences (NASDAQ:VTYX) announced Tuesday that a small mid-stage trial for VTX3232, its experimental therapy for Parkinson’s disease, reached the primary endpoint related to safety and ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...